I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Read more about I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy.
Association of nicotine metabolite ratio and CYP2A6 genotype with smoking cessation treatment in African-American light smokers. Read more about Association of nicotine metabolite ratio and CYP2A6 genotype with smoking cessation treatment in African-American light smokers.
Genetic variation in drug transporters in ethnic populations. Read more about Genetic variation in drug transporters in ethnic populations.
Toward personalized therapy for smoking cessation: a randomized placebo-controlled trial of bupropion. Read more about Toward personalized therapy for smoking cessation: a randomized placebo-controlled trial of bupropion.
Genetic influences in the variation in renal clearance of nicotine and cotinine. Read more about Genetic influences in the variation in renal clearance of nicotine and cotinine.
Clinical pharmacology of nicotine: implications for understanding, preventing, and treating tobacco addiction. Read more about Clinical pharmacology of nicotine: implications for understanding, preventing, and treating tobacco addiction.
Therapeutic drug monitoring of nortriptyline in smoking cessation: a multistudy analysis. Read more about Therapeutic drug monitoring of nortriptyline in smoking cessation: a multistudy analysis.
Effects of genetic variation in the novel organic cation transporter, OCTN1, on the renal clearance of gabapentin. Read more about Effects of genetic variation in the novel organic cation transporter, OCTN1, on the renal clearance of gabapentin.
Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics. Read more about Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics.
Identification of novel CYP2A6*1B variants: the CYP2A6*1B allele is associated with faster in vivo nicotine metabolism. Read more about Identification of novel CYP2A6*1B variants: the CYP2A6*1B allele is associated with faster in vivo nicotine metabolism.
